Researchers have built a series of CRISPR-based platforms that can switch endogenous genes on and, just as critically, dial ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...

On remand from the Federal Circuit, the Patent Trial and Appeal Board on Thursday reaffirmed its decision that The Broad ...

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

CRISPR is a powerful DNA-editing tool that has underpinned huge advancements in human health care in the last decade. It is a ...

Scientists from the University of Sheffield, the MRC Laboratory of Medical Sciences (LMS) and Imperial College London have helped solve a decade-long ...

Editas Medicine announces USPTO reaffirms its prior decision in favour of the Broad Institute in CRISPR/Cas9 interference: Cambridge, Massachusetts Monday, March 30, 2026, 15:00 H ...

Researchers have found that certain bacteria carry a naturally occurring system, built from repurposed CRISPR components, ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...